Opus Genetics (IRD) Cash & Equivalents (2010 - 2026)

Opus Genetics (IRD) has 17 years of Cash & Equivalents data on file, last reported at $60.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 43.44% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.0 million (up 43.44% YoY) and the FY2025 annual result came in at $45.1 million, up 48.71% from the prior year.
• Cash & Equivalents advanced to $60.0 million in Q1 2026 per IRD's latest filing, from $45.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $60.0 million in Q1 2026 and bottomed at $13.9 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $40.0 million (2023), against an average of $37.1 million.
• The widest annual swing landed in 2023, when Cash & Equivalents soared 206.03%; it then plunged 39.96% in 2024.
• Tracing IRD's Cash & Equivalents over 5 years: stood at $42.6 million in 2022, then gained by 18.45% to $50.5 million in 2023, then tumbled by 39.96% to $30.3 million in 2024, then surged by 48.71% to $45.1 million in 2025, then soared by 32.97% to $60.0 million in 2026.
• Per Business Quant, the three latest IRD Cash & Equivalents figures stand at $60.0 million (Q1 2026), $45.1 million (Q4 2025), and $30.8 million (Q3 2025).

Peer Comparison